S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
S&P 500   3,849.62
DOW   30,937.04
QQQ   328.59
Log in
NASDAQ:OPTN

OptiNose Stock Forecast, Price & News

$4.29
-0.16 (-3.60 %)
(As of 01/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$4.27
Now: $4.29
$4.49
50-Day Range
$4.06
MA: $4.30
$4.73
52-Week Range
$3.14
Now: $4.29
$10.00
Volume388,371 shs
Average Volume387,429 shs
Market Capitalization$223.43 million
P/E RatioN/A
Dividend YieldN/A
Beta1.03
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It is also developing XHANCE, which is in Phase IIIb clinical trial for the treatment of chronic sinusitis; and OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder. The company has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail (sumatriptan nasal powder) to treat migraine in adults; and Inexia Limited to develop, manufacture, import, and sale products containing orexin receptor agonist and/or orexin receptor positive modulator molecules for the treatment, diagnosis, or prevention of human diseases or conditions associated primarily with orexin receptor agonism and orexin receptor positive modulation. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
OptiNose logo

MarketRank

Overall MarketRank

1.61 out of 5 stars

Medical Sector

299th out of 1,925 stocks

Pharmaceutical Preparations Industry

152nd out of 773 stocks

Analyst Opinion: 3.3Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OPTN
CUSIPN/A
Phone267-364-3500
Employees221
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$34.63 million
Book Value$1.48 per share

Profitability

Net Income$-110,050,000.00
Net Margins-230.14%

Miscellaneous

Market Cap$223.43 million
Next Earnings Date3/4/2021 (Estimated)
OptionableNot Optionable
$4.29
-0.16 (-3.60 %)
(As of 01/26/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OPTN News and Ratings via Email

Sign-up to receive the latest news and ratings for OPTN and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











OptiNose (NASDAQ:OPTN) Frequently Asked Questions

How has OptiNose's stock been impacted by Coronavirus (COVID-19)?

OptiNose's stock was trading at $5.06 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OPTN stock has decreased by 15.2% and is now trading at $4.29.
View which stocks have been most impacted by COVID-19
.

Is OptiNose a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OptiNose in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" OptiNose stock.
View analyst ratings for OptiNose
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than OptiNose?

Wall Street analysts have given OptiNose a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but OptiNose wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is OptiNose's next earnings date?

OptiNose is scheduled to release its next quarterly earnings announcement on Thursday, March 4th 2021.
View our earnings forecast for OptiNose
.

How were OptiNose's earnings last quarter?

OptiNose, Inc. (NASDAQ:OPTN) issued its quarterly earnings data on Thursday, November, 5th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.56) by $0.13. The company earned $15.44 million during the quarter, compared to analysts' expectations of $15.40 million. OptiNose had a negative trailing twelve-month return on equity of 294.64% and a negative net margin of 230.14%.
View OptiNose's earnings history
.

What price target have analysts set for OPTN?

3 Wall Street analysts have issued 1 year price objectives for OptiNose's stock. Their forecasts range from $17.00 to $21.00. On average, they expect OptiNose's stock price to reach $19.00 in the next year. This suggests a possible upside of 342.9% from the stock's current price.
View analysts' price targets for OptiNose
or view Wall Street analyst' top-rated stocks.

Who are some of OptiNose's key competitors?

What other stocks do shareholders of OptiNose own?

Who are OptiNose's key executives?

OptiNose's management team includes the following people:
  • Mr. Peter K. Miller, CEO & Director (Age 59, Pay $1.02M)
  • Dr. Ramy A. Mahmoud M.D., M.P.H., Pres & COO (Age 55, Pay $743.72k)
  • Mr. Keith Alan Goldan, Chief Financial Officer (Age 49, Pay $603.73k)
  • Mr. Michael F. Marino, Chief Legal Officer & Corp. Sec. (Age 44, Pay $708.26k)
  • Mr. Jonathan Neely, VP of Investor Relations & Bus. Operations
  • Ms. Karen E. Brophy, VP of HR (Age 57)
  • Mr. John Messina, Sr. VP of Clinical Devel. & Medical Affairs
  • Mr. Victor M. Clavelli, Chief Commercial Officer (Age 47)
  • Ms. Helena Kyttari Djupesland, Co-Founder of Optinose AS (Norway) & Co-CEO of Optinose AS (Norway)

When did OptiNose IPO?

(OPTN) raised $101 million in an initial public offering on Friday, October 13th 2017. The company issued 6,300,000 shares at $15.00-$17.00 per share. Jefferies, Piper Jaffray, BMO Capital Markets and RBC Capital Markets served as the underwriters for the IPO.

What is OptiNose's stock symbol?

OptiNose trades on the NASDAQ under the ticker symbol "OPTN."

Who are OptiNose's major shareholders?

OptiNose's stock is owned by a variety of retail and institutional investors. Top institutional investors include Paradigm Capital Management Inc. NY (4.80%). Company insiders that own OptiNose stock include Avista Capital Partners Ii Gp,, Joseph C Scodari, Keith A Goldan, Michael F Marino III, Peter K Miller, Ramy A Mahmoud and Thomas Edward Gibbs.
View institutional ownership trends for OptiNose
.

Which institutional investors are buying OptiNose stock?

OPTN stock was acquired by a variety of institutional investors in the last quarter, including Paradigm Capital Management Inc. NY. Company insiders that have bought OptiNose stock in the last two years include Joseph C Scodari, Keith A Goldan, and Michael F Marino III.
View insider buying and selling activity for OptiNose
or or view top insider-buying stocks.

How do I buy shares of OptiNose?

Shares of OPTN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is OptiNose's stock price today?

One share of OPTN stock can currently be purchased for approximately $4.29.

How big of a company is OptiNose?

OptiNose has a market capitalization of $223.43 million and generates $34.63 million in revenue each year. The company earns $-110,050,000.00 in net income (profit) each year or ($2.63) on an earnings per share basis. OptiNose employs 221 workers across the globe.

What is OptiNose's official website?

The official website for OptiNose is www.optinose.com.

How can I contact OptiNose?

OptiNose's mailing address is 1020 STONY HILL ROAD SUITE 300, YARDLEY PA, 19067. The company can be reached via phone at 267-364-3500 or via email at [email protected]

This page was last updated on 1/27/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.